8 Pos - Senti Biosciences, INC. (SNTI) — SEC Filings

Overview

8 Pos - Senti Biosciences, INC. (SNTI) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a S filed on Apr 24, 2026: Senti Biosciences, Inc. filed an S-8 POS form on April 24, 2026, registering an unspecified number of securities to be offered under its employee benefit plans. This filing is a post-effective amendment, indicating updates or additions to previously registered securities for employee compensation.

Sentiment Summary

Across 41 filings, the sentiment breakdown is: 1 bullish, 4 bearish, 35 neutral, 1 mixed. The dominant filing sentiment for 8 Pos - Senti Biosciences, INC. is neutral.

Filing Type Overview

8 Pos - Senti Biosciences, INC. (SNTI) has filed 2 S, 25 8-K, 3 10-K, 6 10-Q, 3 DEF 14A, 1 SC 13D/A, 1 10-K/A with the SEC between Jan 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (41)

• Senti Biosciences Files S-8 POS for Employee Benefit Plans — S · Apr 24, 2026 Risk: low
  Senti Biosciences, Inc. filed an S-8 POS form on April 24, 2026, registering an unspecified number of securities to be offered under its employee benefit plans.
• Senti Biosciences Files S-8 POS for Employee Stock Plans — S · Apr 24, 2026 Risk: low
  Senti Biosciences, Inc. filed an S-8 POS form on April 24, 2026, registering an unspecified number of securities to be offered under its employee benefit plans.
• Senti Biosciences Files 8-K — 8-K · Apr 1, 2026 Risk: low
  Senti Biosciences, Inc. filed an 8-K on April 1, 2026, to report other events. The filing does not contain specific financial figures or new material events bey
• Senti Bio's SENTI-202 Shows Promise in AML, Secures FDA Designations — 10-K · Mar 27, 2026 Risk: high
  Senti Biosciences, Inc. (SNTI) is a clinical-stage biotechnology company focused on developing next-generation cell and gene therapies using its proprietary gen
• 8-K Filing — 8-K · Mar 27, 2026
• 8-K Filing — 8-K · Dec 9, 2025
• Senti Biosciences' Cash Dwindles Amid Rising R&D, Going Concern Looms — 10-Q · Nov 13, 2025 Risk: high
  Senti Biosciences, Inc. (SNTI) reported a net loss of $46.97 million for the nine months ended September 30, 2025, a 10% improvement from the $52.18 million net
• Senti Biosciences Remains Pre-Revenue, Focuses on GeneFab Development — 10-Q · Aug 7, 2025 Risk: high
  Senti Biosciences, Inc. (SNTI) reported no revenue for the three and six months ended June 30, 2025, consistent with the prior year periods, indicating its pre-
• Senti Biosciences Files 8-K on Executive Changes — 8-K · Jul 18, 2025 Risk: medium
  Senti Biosciences, Inc. filed an 8-K on July 18, 2025, reporting on the departure of directors or certain officers, the election of directors, the appointment o
• Senti Biosciences Reports on Shareholder Votes — 8-K · Jun 30, 2025 Risk: low
  Senti Biosciences, Inc. filed an 8-K on June 30, 2025, reporting on matters submitted to a vote of security holders as of June 25, 2025. The filing details the
• Senti Biosciences Files 8-K — 8-K · Jun 18, 2025 Risk: low
  Senti Biosciences, Inc. filed an 8-K on June 18, 2025, to report an event under Regulation FD Disclosure and Other Events. The filing does not contain specific
• Senti Biosciences Files Q1 2025 10-Q — 10-Q · May 6, 2025 Risk: medium
  Senti Biosciences, Inc. filed its quarterly report for the period ending March 31, 2025. The company, previously known as Dynamics Special Purpose Corp., is foc
• Senti Biosciences Files Proxy Statement for June Meeting — DEF 14A · Apr 30, 2025 Risk: low
  Senti Biosciences, Inc. filed its definitive proxy statement on April 30, 2025, for its annual meeting on June 25, 2025. The company, formerly known as Dynamics
• Senti Biosciences Files 8-K on Financials and Operations — 8-K · Apr 28, 2025 Risk: medium
  Senti Biosciences, Inc. filed an 8-K on April 28, 2025, reporting on its results of operations and financial condition. The filing also includes Regulation FD d
• Senti Biosciences Enters Material Definitive Agreement — 8-K · Mar 24, 2025 Risk: medium
  On March 20, 2025, Senti Biosciences, Inc. entered into a material definitive agreement. The company, previously known as Dynamics Special Purpose Corp., is inc
• Senti Biosciences Files 2024 10-K — 10-K · Mar 20, 2025 Risk: medium
  Senti Biosciences, Inc. filed its 10-K for the fiscal year ending December 31, 2024. The company, previously known as Dynamics Special Purpose Corp., is in the
• Senti Biosciences Board Changes and Officer Compensation — 8-K · Mar 10, 2025 Risk: medium
  Senti Biosciences, Inc. announced on March 6, 2025, a change in its board of directors, with the departure of Dr. Philip P. Pesce and the appointment of Dr. Jon
• Senti Biosciences Files 8-K on Shareholder Votes & Financials — 8-K · Mar 7, 2025 Risk: low
  Senti Biosciences, Inc. filed an 8-K on March 7, 2025, reporting on matters submitted to a vote of security holders and financial statements. The filing pertain
• Senti Biosciences Files 8-K: Director Departs, Disclosures Made — 8-K · Feb 25, 2025 Risk: medium
  Senti Biosciences, Inc. announced on February 23, 2025, the departure of Director Dr. Philip P. Pescatore. The company also reported on compensatory arrangement
• Senti Biosciences Reports Executive and Director Changes — 8-K · Feb 6, 2025 Risk: medium
  Senti Biosciences, Inc. filed an 8-K on February 6, 2025, reporting changes effective January 31, 2025. The filing details the departure of directors or certain
• Senti Biosciences Files Definitive Proxy Statement — DEF 14A · Jan 27, 2025 Risk: low
  Senti Biosciences, Inc. filed a Definitive Proxy Statement (DEF 14A) on January 27, 2025, for the fiscal year ending December 31, 2024. The filing concerns the
• Senti Biosciences Files 8-K on Financial Obligations & Equity Sales — 8-K · Jan 6, 2025 Risk: medium
  On December 31, 2024, Senti Biosciences, Inc. filed an 8-K report detailing several key events. The company entered into a direct financial obligation and also
• Senti Biosciences Files 8-K — 8-K · Dec 16, 2024 Risk: low
  On December 16, 2024, Senti Biosciences, Inc. filed an 8-K report. The filing primarily concerns other events and financial statements/exhibits, with no specifi
• NEA 15 Amends Senti Biosciences Stake — SC 13D/A · Dec 4, 2024 Risk: medium
  New Enterprise Associates 15, L.P. (NEA 15) and its affiliated group members, including NEA 15 GP, LLC, Anthony A. Florence, Jr., Forest Baskett, and Mohamad H.
• Senti Biosciences Files 8-K — 8-K · Dec 3, 2024 Risk: low
  Senti Biosciences, Inc. filed an 8-K on December 3, 2024, reporting other events and financial statements. The company, formerly known as Dynamics Special Purpo
• Senti Biosciences Files 8-K — 8-K · Dec 2, 2024 Risk: low
  On December 2, 2024, Senti Biosciences, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, and a Regulation FD disclosur
• Senti Biosciences Files Q3 2024 10-Q — 10-Q · Nov 14, 2024 Risk: medium
  Senti Biosciences, Inc. filed its 10-Q for the period ending September 30, 2024. The company, focused on biological products, reported its financial status and
• Senti Biosciences Faces Delisting Notice — 8-K · Oct 25, 2024 Risk: high
  Senti Biosciences, Inc. filed an 8-K on October 25, 2024, to report a notice of delisting or failure to satisfy a continued listing rule. The earliest event rep
• Senti Biosciences Enters Material Definitive Agreement — 8-K · Sep 27, 2024 Risk: medium
  On September 23, 2024, Senti Biosciences, Inc. entered into a Material Definitive Agreement. The filing does not disclose specific details of the agreement or a
• Senti Biosciences Files Q2 2024 10-Q — 10-Q · Aug 13, 2024 Risk: medium
  Senti Biosciences, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported its financial results and provided updates on its business acti
• Senti Biosciences Files 8-K for Bylaw Amendments — 8-K · Jul 17, 2024 Risk: low
  Senti Biosciences, Inc. filed an 8-K on July 17, 2024, reporting amendments to its articles of incorporation or bylaws and financial statements. The company, in
• Senti Biosciences Enters Material Definitive Agreement — 8-K · Jul 16, 2024 Risk: medium
  On July 16, 2024, Senti Biosciences, Inc. filed an 8-K to report the entry into a material definitive agreement. The filing does not disclose specific details o
• Senti Biosciences Files 8-K on Security Holder Matters — 8-K · Jul 12, 2024 Risk: medium
  Senti Biosciences, Inc. filed an 8-K on July 12, 2024, reporting on events that occurred on July 10, 2024. The filing indicates material modifications to the ri
• Senti Biosciences Files Proxy Statement for July Meeting — DEF 14A · May 29, 2024 Risk: medium
  Senti Biosciences, Inc. filed a Definitive Proxy Statement (DEF 14A) on May 29, 2024, for its annual meeting on July 10, 2024. The filing concerns the election
• Senti Biosciences Names New CEO, Board Changes — 8-K · May 17, 2024 Risk: medium
  Senti Biosciences, Inc. announced on May 14, 2024, a series of executive and board changes. Dr. Philip P. Sia has been appointed as the new Chief Executive Offi
• Senti Biosciences, Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 9, 2024 Risk: low
  Senti Biosciences, Inc. (SNTI) filed a Quarterly Report (10-Q) with the SEC on May 9, 2024. Senti Biosciences, Inc. filed a 10-Q report for the period ending Ma
• Senti Bio Announces Leadership Changes — 8-K · May 2, 2024 Risk: medium
  Senti Biosciences, Inc. announced on April 26, 2024, the departure of Chief Medical Officer Dr. Philip Arlen and the election of Dr. Michael J. Yaszemski as a n
• Senti Biosciences Files 10-K/A Amendment No. 1 for Fiscal Year Ended Dec 31, 2023 — 10-K/A · Apr 26, 2024 Risk: low
  Senti Biosciences, Inc. (SNTI) filed a Amended Annual Report (10-K/A) with the SEC on April 26, 2024. Senti Biosciences, Inc. filed an amendment (10-K/A) to its
• Senti Biosciences, Inc. Files 2023 Annual Report on Form 10-K — 10-K · Mar 21, 2024 Risk:
  Senti Biosciences, Inc. (SNTI) filed a Annual Report (10-K) with the SEC on March 21, 2024. Senti Biosciences, Inc. filed its annual report for the fiscal year
• Senti Biosciences Faces Nasdaq Delisting for Low Bid Price — 8-K · Feb 6, 2024
  Senti Biosciences, Inc. (SNTI) announced on February 6, 2024, that it received a delisting notice from the Nasdaq Stock Market because its common stock failed t
• Senti Biosciences Reports Exit/Disposal Activities on Jan 3 — 8-K · Jan 5, 2024
  Senti Biosciences, Inc. filed an 8-K on January 5, 2024, reporting an event that occurred on January 3, 2024. This filing indicates that the company is undergoi

Risk Profile

Risk Assessment: Of SNTI's 36 recent filings, 4 were flagged as high-risk, 18 as medium-risk, and 14 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Financial Highlights

Key financial metrics from 8 Pos - Senti Biosciences, INC.'s most recent 10-K filing (Mar 27, 2026):

• Revenue: N/A
• Net Income: N/A
• EPS: N/A
• Debt-to-Equity: N/A
• Cash Position: N/A
• Operating Margin: N/A
• Total Assets: N/A
• Total Debt: N/A

Key Executives

• Dr. Philip P. Pesce
• Dr. Jonathan G. Drachman
• Dr. Philip P. Pescatore
• Anthony A. Florence, Jr.
• Forest Baskett
• Mohamad H. Makhzoumi
• Philip P. Sia
• Timothy J. Miller
• Jonathan M. Roth
• Dr. Philip Arlen
• Dr. Michael J. Yaszemski

Industry Context

The cell and gene therapy sector is characterized by rapid innovation and significant investment, driven by the potential to offer curative treatments for previously intractable diseases. Key trends include the development of allogeneic ('off-the-shelf') therapies to overcome manufacturing and cost hurdles associated with autologous treatments, and the increasing sophistication of genetic engineering platforms like Senti's gene circuits to enhance therapeutic precision and control. The competitive landscape is intense, with numerous biotech and pharmaceutical companies vying for leadership in oncology and rare diseases.

Top Tags

8-K (5) · Biotechnology (5) · 10-Q (5) · corporate-governance (5) · biotech (4) · financials (4) · SEC Filing (3) · Gene Therapy (3) · Clinical Stage (3) · filing (3)

Key Numbers

• Market Value of Non-Affiliate Common Stock: $53.2M — As of June 30, 2025, indicating a smaller market capitalization.
• Overall Response Rate: 50% — Observed in Phase 1 clinical trial for SENTI-202 in AML patients.
• Complete Remission/CRh Rate: 42% — Achieved by Phase 1 AML patients treated with SENTI-202.
• Median Duration of Composite Complete Remission: 7.6 months — Observed across all patients in the SENTI-202 Phase 1 trial.
• AML Five-Year Survival Rate: 31.9% — Highlights the high unmet medical need SENTI-202 aims to address.
• Shares Outstanding: 31,144,497 — As of March 19, 2026.
• Cash and cash equivalents: $12.2M — Decreased from $48.3M at Dec 31, 2024, insufficient for one year of operations.
• Net loss (9 months): $47.0M — Improved from $52.2M in prior year, but still substantial.
• Accumulated deficit: $344.1M — Increased from $297.1M at Dec 31, 2024, reflecting ongoing losses.
• Total operating expenses (9 months): $50.1M — Increased from $44.9M in prior year, driven by R&D.
• GeneFab past-due rent: $4.7M — Significant receivable from related party, posing credit risk.
• Shares outstanding: 26,290,838 — Increased from 4,829,035 at Dec 31, 2024, indicating significant dilution.
• Net cash used in operating activities (9 months): $36.6M — Increased from $27.9M in prior year, showing accelerated cash burn.
• Basic and diluted net loss per share (Q3): $0.69 — Lower than $6.31 in Q3 2024, but on a significantly higher share count.
• Revenue: $0 — for the three and six months ended June 30, 2025, and prior periods, indicating pre-revenue stage

Frequently Asked Questions